Amgen Inc
NASDAQ:AMGN
Amgen Inc
Revenue
Amgen Inc
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$33.4B
|
CAGR 3-Years
9%
|
CAGR 5-Years
7%
|
CAGR 10-Years
5%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$56.3B
|
CAGR 3-Years
0%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$28.8B
|
CAGR 3-Years
2%
|
CAGR 5-Years
5%
|
CAGR 10-Years
1%
|
|
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
Revenue
$2.2B
|
CAGR 3-Years
39%
|
CAGR 5-Years
59%
|
CAGR 10-Years
46%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$11B
|
CAGR 3-Years
13%
|
CAGR 5-Years
21%
|
CAGR 10-Years
34%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$14.2B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
13%
|
CAGR 10-Years
18%
|
|
Amgen Inc
Revenue Breakdown
Breakdown by Geography
Amgen Inc
|
Total Revenue:
33.4B
USD
|
|
United States:
23.9B
USD
|
|
Row:
9.6B
USD
|
Breakdown by Segments
Amgen Inc
|
Total Revenue:
33.4B
USD
|
|
Other Products:
5.6B
USD
|
|
Prolia:
4.4B
USD
|
|
Enbrel:
3.3B
USD
|
Amgen Inc
Glance View
Amgen Inc., a towering figure in the biopharmaceutical industry, started its journey in the early 1980s in Thousand Oaks, California, with a visionary commitment to tapping into the potential of recombinant DNA technology. This leap into biotechnology allowed the company to produce vital proteins that the body naturally lacks in certain medical conditions. Concentrating on serious illnesses such as cancer, kidney failure, and rheumatoid arthritis, Amgen transformed itself over the decades from a novel research lab into a global powerhouse, rolling out revolutionary therapies like Epogen and Neulasta. These blockbuster drugs, designed to treat anemia and prevent infections in chemotherapy patients, catapulted Amgen into the echelon of companies that not only evolve with science but also shape its trajectory. Today, Amgen thrives by blending its innovative science with strategic acquisitions, expanding its pipeline beyond merely biological drugs to include biosimilars and small molecule medicines. The company's revenue stream relies heavily on its existing successful therapies while also banking on the future with investments in genetic research and novel drug developments. By leveraging their expertise in biotechnology and clinical trials, Amgen is able to bring new products to market and navigate the complex regulatory landscape efficiently. The firm expertly balances risk and reward, ensuring a steady influx of cash flow through both established product lines and the advent of new therapies. Thus, Amgen, with its robust portfolio and strategic business maneuvers, continues to play a pivotal role in enhancing patient outcomes while reinforcing its position as a leader in the biopharmaceutical realm.
See Also
What is Amgen Inc's Revenue?
Revenue
33.4B
USD
Based on the financial report for Dec 31, 2024, Amgen Inc's Revenue amounts to 33.4B USD.
What is Amgen Inc's Revenue growth rate?
Revenue CAGR 10Y
5%
Over the last year, the Revenue growth was 19%. The average annual Revenue growth rates for Amgen Inc have been 9% over the past three years , 7% over the past five years , and 5% over the past ten years .
You don't have any saved screeners yet